Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Quidel Corporation    QDEL

QUIDEL CORPORATION

(QDEL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/30/2020 12/01/2020 12/02/2020 12/03/2020 12/04/2020 Date
195.05(c) 188.95(c) 198.98(c) 200.99(c) 193.57(c) Last
1 030 223 708 196 899 954 830 490 602 525 Volume
+3.75% -3.13% +5.31% +1.01% -3.69% Change
More quotes
Financials (USD)
Sales 2020 1 657 M - -
Net income 2020 773 M - -
Net cash position 2020 150 M - -
P/E ratio 2020 10,9x
Yield 2020 -
Sales 2021 2 998 M - -
Net income 2021 1 433 M - -
Net cash position 2021 2 371 M - -
P/E ratio 2021 5,24x
Yield 2021 -
Capitalization 8 143 M 8 143 M -
EV / Sales 2020 4,82x
EV / Sales 2021 1,93x
Nbr of Employees 1 250
Free-Float 88,2%
More Financials
Company
Quidel Corp. is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: rapid immunoassays, cardiac immunoassay, specialized diagnostic solutions and molecular diagnostic solutions. It sells its products directly to end users and distributors, in each case, for professional use in physician offices,... 
More about the company
Notations Surperformance© of Quidel Corporation
Trading Rating : Investor Rating :
More Ratings
All news about QUIDEL CORPORATION
11/19QUIDEL CORPORATION : Hosts Upcoming Webinar to Help Health Professionals Disting..
BU
11/13QUIDEL CORP /DE/ : Entry into a Material Definitive Agreement, Amendments to Art..
AQ
11/10QUIDEL : to Present at Upcoming Conferences
BU
11/10QUIDEL CORPORATION : Triple Winner in International MarCom Awards Competition
BU
11/07Many Nursing Homes Shun Free Covid-19 Testing Equipment
DJ
11/03QUIDEL : to Host Virtual Investor Day on November 12, 2020
BU
11/03QUIDEL : U.S. FDA warns about false positive results from COVID-19 antigen tests
RE
10/30QUIDEL : DE/ Management's Discussion and Analysis of Financial Condition and Res..
AQ
10/29QUIDEL : 3Q Earnings Snapshot
AQ
10/29QUIDEL CORP /DE/ : Results of Operations and Financial Condition, Financial Stat..
AQ
10/29QUIDEL : Reports Third Quarter 2020 Financial Results
BU
10/22QUIDEL CORPORATION : Joins Global Lyme Alliance as Sponsor for the GLA ‘Fi..
BU
10/19QUIDEL : to Hold Third Fiscal Quarter 2020 Financial Results Conference Call on ..
BU
10/09BECTON DICKINSON AND : Trump Administration Orders Nevada to Allow Rapid Covid-1..
DJ
10/09Nevada's ban on Quidel and Becton Dickinson COVID-19 tests violates law -HHS ..
RE
More news
News in other languages on QUIDEL CORPORATION
09/24Schnelltests - Hoffnung für Corona-geplagte Airlines
08/14QUIDEL : Le test Lyra® Direct SARS-CoV-2 Assay de Quidel reçoit l'autorisation d..
05/11EN DIRECT DES MARCHES : Renault, Air France-KLM, ArcelorMittal, Groupe ADP, N..
05/11C'est la reprise !
2014QUIDEL CORPORATION : publication des résultats trimestriels
More news
Chart QUIDEL CORPORATION
Duration : Period :
Quidel Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QUIDEL CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 302,00 $
Last Close Price 193,57 $
Spread / Highest target 91,7%
Spread / Average Target 56,0%
Spread / Lowest Target -9,59%
EPS Revisions
Managers
NameTitle
Douglas C. Bryant President, Chief Executive Officer & Director
Kenneth F. Buechler Chairman
Robert Joseph Bujarski Chief Operating Officer
Randall J. Steward Chief Financial Officer
Werner Kroll Senior Vice President-Research & Development
Sector and Competitors